keyword
MENU ▼
Read by QxMD icon Read
search

Infliximab

keyword
https://www.readbyqxmd.com/read/28337644/cns-demyelination-with-tnf-%C3%AE-blockers
#1
REVIEW
Elissavet Kemanetzoglou, Elisabeth Andreadou
Tumor necrosis factor-α (TNF-α) blockers are a popular therapeutic choice in a number of inflammatory diseases. Thus far, five TNF- α blockers have been approved for clinical use (etanercept, infliximab, adalimumab, golimumab. and certolizumab). Despite being considered relatively safe, serious side effects associated with immune suppression have been reported, including central and peripheral nervous system (CNS) demyelinating disorders. It is still elusive whether these events are mere coincidence or a side effect of anti-TNF-α use...
April 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/28337236/adalimumab-for-endoscopic-and-histopathological-mucosal-healing-in-paediatric-patients-with-moderate-to-severe-crohn-s-disease
#2
Edyta Szymanska, Maciej Dadalski, Wieslawa Grajkowska, Sylwia Szymanska, Maciej Pronicki, Jaroslaw Kierkus
INTRODUCTION: Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn's disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much less data for adalimumab (ADA), and none concerning MH on histopathological examination. AIM: To assess the impact of biological therapy with ADA on both endoscopic and histopathological MH in paediatric patients with CD...
2017: Przegla̜d Gastroenterologiczny
https://www.readbyqxmd.com/read/28336735/risk-of-tuberculosis-in-patients-treated-with-tnf-%C3%AE-antagonists-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials
#3
Zheng Zhang, Wei Fan, Gui Yang, Zhigao Xu, June Wang, Qingyuan Cheng, Mingxia Yu
OBJECTIVES: An increased risk of tuberculosis (TB) has been reported in patients treated with TNF-α antagonists, an issue that has been highlighted in a WHO black box warning. This review aimed to assess the risk of TB in patients undergoing TNF-α antagonists treatment. METHODS: A systematic literature search for randomised controlled trials (RCTs) was performed in MEDLINE, Embase and Cochrane library and studies selected for inclusion according to predefined criteria...
March 22, 2017: BMJ Open
https://www.readbyqxmd.com/read/28333755/treatment-persistence-for-infliximab-versus-adalimumab-in-crohn-s-disease-a-14-year-single-center-experience
#4
Pablo Olivera, Linda Thiriet, Amandine Luc, Cedric Baumann, Silvio Danese, Laurent Peyrin-Biroulet
BACKGROUND: Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn's disease (CD). There are few published data on the treatment persistence of IFX and ADA in patients with CD. METHODS: We aimed to compare the persistence rates of IFX versus ADA as first- and second-line tumor necrosis factor antagonist (anti-TNF), to identify factors potentially associated with persistence, and to evaluate reasons for treatment withdrawal in CD patients...
March 16, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28331376/long-term-safety-and-efficacy-of-biosimilar-infliximab-among-patients-with-inflammatory-arthritis-switched-from-reference-product
#5
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O'Sullivan, Ann Maria Curran, John J Carey
PURPOSE: To evaluate the efficacy and safety of the biosimilar infliximab in adult patients with inflammatory arthritis switched from reference product in our center. PATIENTS AND METHODS: In April 2014, patients attending our rheumatology service for infliximab infusions were switched from reference product to the biosimilar infliximab following consent and hospital approval. RESULTS: Around 34 patients with inflammatory arthritis were switched from reference product to biosimilar infliximab in 2014: 50% female, mean age 55 years (standard deviation=12...
2017: Open Access Rheumatology: Research and Reviews
https://www.readbyqxmd.com/read/28331299/assessing-physician-and-patient-acceptance-of-infliximab-biosimilars-in-rheumatoid-arthritis-ankylosing-spondyloarthritis-and-psoriatic-arthritis-across-germany
#6
John Waller, Emma Sullivan, James Piercy, Christopher M Black, Sumesh Kachroo
OBJECTIVES: We examined rheumatologists' motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behavior and explored patient attitudes to biosimilars. METHODS: Data were taken from the Adelphi Real World Biosimilars Programme, a real-world, cross-sectional study undertaken with German rheumatologists and patients with rheumatoid arthritis, ankylosing spondyloarthritis or psoriatic arthritis in 2015-2016. Rheumatologists provided data on their prescribing behavior and attitudes toward biosimilars and invited the next eight eligible consecutive consulting patients to complete a questionnaire...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28329591/an-erythematous-papular-eruption-in-a-woman-with-crohn-disease-treated-with-infliximab
#7
Hannah E Howard, Jeffrey P Zwerner, Jeffrey Byers, Eric Tkaczyk
We report the case of a 44-year-old woman with a history of Crohn disease treated with infliximab who presented with erythematous papules and plaques on the upper extremities accompanied by fevers. She was subsequently diagnosed with palisaded neutrophilic and granulomatous dermatitis (PNGD). Whereas immune-complex mediated diseases such as rheumatoid arthritis and systemic lupus erythematosus are most commonly associated, inflammatory bowel disease deserves increased consideration as one of the systemic diseases that can present with PNGD...
October 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329508/tumor-necrosis-factor-antagonist-induced-psoriasis-in-a-3-year-old-boy-with-kawasaki-disease
#8
Lauren Geller, Roselyn Kellen
Tumor necrosis factor (TNF) antagonists have beenknown to trigger new-onset psoriasis in adult andpediatric patients. Here we report a case of TNFantagonist-induced psoriasis in a 3-year-old boytreated with infliximab for Kawasaki disease. Ourpatient is a 3-year-old boy with Kawasaki diseaseunresponsive to intravenous immunoglobulinwho was then treated with one dose of infliximab.A few days later he developed psoriatic plaqueson the face and extremities. The psoriatic plaqueswere treated with topical calcineurin inhibitors andtopical corticosteroids, with marked improvement...
February 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28326566/systematic-review-with-meta-analysis-comparative-efficacy-of-biologics-for-induction-and-maintenance-of-mucosal-healing-in-crohn-s-disease-and-ulcerative-colitis-controlled-trials
#9
REVIEW
A Cholapranee, G S Hazlewood, G G Kaplan, L Peyrin-Biroulet, A N Ananthakrishnan
BACKGROUND: Mucosal healing is an important therapeutic endpoint in the management of Crohn's disease (CD) and ulcerative colitis (UC). Limited data exist regarding the comparative efficacy of various therapies in achieving this outcome. AIM: To perform a systematic review and meta-analysis of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis. METHODS: We performed a systematic review and meta-analysis of randomised controlled trials (RCT) examining mucosal healing as an endpoint of immunosuppressives, anti-tumour necrosis factor α (anti-TNF) or anti-integrin monoclonal antibody therapy for moderate-to-severe CD or UC...
March 22, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28325214/antibody-based-cancer-therapy-successful-agents-and-novel-approaches
#10
D Hendriks, G Choi, M de Bruyn, V R Wiersma, E Bremer
Since their discovery, antibodies have been viewed as ideal candidates or "magic bullets" for use in targeted therapy in the fields of cancer, autoimmunity, and chronic inflammatory disorders. A wave of antibody-dedicated research followed, which resulted in the clinical approval of a first generation of monoclonal antibodies for cancer therapy such as rituximab (1997) and cetuximab (2004), and infliximab (2002) for the treatment of autoimmune diseases. More recently, the development of antibodies that prevent checkpoint-mediated inhibition of T cell responses invigorated the field of cancer immunotherapy...
2017: International Review of Cell and Molecular Biology
https://www.readbyqxmd.com/read/28321492/anti-toxoplasma-antibodies-in-egyptian-rheumatoid-arthritis-patients
#11
Abeer A El-Henawy, Eman Abdel Razek Hafez, Nairmen Nabih, Naglaa M Shalaby, Mervat Mashaly
OBJECTIVE: To assess seroprevalence of anti-Toxoplasma gondii antibodies; both IgG and IgM in Egyptian rheumatoid arthritis (RA) patients versus a non-RA group and to compare anti-Toxoplasma antibodies seroprevalence among RA patients receiving traditional treatment and RA patients treated with biologic drug. METHODS: 60 RA patients and 60 healthy controls were enrolled in the study. Patients were categorized into two groups: one group included 30 patients receiving disease modifying anti-rheumatic drugs (DMARDs), while the other group included 30 patients receiving biologic agent, infliximab, a TNF-α antagonist...
March 20, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28320544/-about-a-case-of-laryngeal-location-of-sapho
#12
L Vatin, E Jean, D Rivière, M Montava, A Giovanni, P Dessi, A Lagier
INTRODUCTION: Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) is a syndrome that combines dermatological, articular and osseous inflammatory manifestations. Bilateral laryngeal immobility relative to cricoarytenoid joint origin is very uncommon. This article presents a case of bilateral cricoarytenoid joint ankylosis in a SAPHO syndrome context. CASE REPORT: A 53-year-old patient presenting with a two year history of intermittent bouts of dyspnea. A SAPHO syndrome was discussed on repeated thoracic CT-scan...
March 17, 2017: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/28318043/the-effects-of-pregnancy-on-the-pharmacokinetics-of-infliximab-and-adalimumab-in-inflammatory-bowel-disease
#13
C H Seow, Y Leung, N Vande Casteele, E Ehteshami Afshar, D Tanyingoh, G Bindra, M J Stewart, P L Beck, G G Kaplan, S Ghosh, R Panaccione
BACKGROUND: Transplacental transfer of infliximab and adalimumab results in detectable drug levels in the cord blood and infant. AIM: To determine if pregnancy influenced the pharmacokinetics of anti-TNF agents in women with inflammatory bowel disease. METHODS: Twenty-five women from the University of Calgary inflammatory bowel disease(IBD) pregnancy clinic on maintenance infliximab or adalimumab were recruited prospectively with serum bio-banking performed each trimester...
March 20, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28306596/biosimilars-implications-for-rheumatoid-arthritis-therapy
#14
Stanley Cohen, Jonathan Kay
PURPOSE OF REVIEW: Abbreviated pathways for the approval of biosimilars have been established in the European Union (EU), the United States, and other countries. Biosimilar TNF inhibitors have been available in South Korea and the EU since 2012 and 2013, respectively, and the first biosimilar infliximab was introduced to the clinic in the United States in November 2016. Five TNF inhibitor biosimilars have now been approved, and many other biosimilars to treat rheumatoid arthritis and other inflammatory diseases are in development...
March 16, 2017: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/28300922/paradoxical-psoriasis-after-the-use-of-anti-tnf-in-a-patient-with-rheumatoid-arthritis
#15
Jaqueline Barbeito de Vasconcellos, Daniele do Nascimento Pereira, Thiago Jeunon de Sousa Vargas, Roger Abramino Levy, Geraldo da Rocha Castelar Pinheiro, Ígor Brum Cursi
The use of tumor necrosis factor antagonists (anti-TNF) has become a usual practice to treat various inflammatory diseases. Although indicated for the treatment of psoriasis, anti-TNF may paradoxically trigger a psoriasiform condition. We present a case of a female patient who, during the use of infliximab for rheumatoid arthritis, developed psoriasis. In an attempt to switch anti-TNF class, we observed a cumulative worsening of the lesions requiring suspension of the immunobiological agent and the introduction of other drugs for clinical control...
September 2016: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28300604/altered-activation-of-peripheral-cd8-t-cells-in-pediatric-crohn-s-disease
#16
Csaba Orbán, Dolóresz Szabó, Anna Bajnok, Barna Vásárhelyi, Tivadar Tulassay, András Arató, Gábor Veres, Gergely Toldi
AIM: Although Crohn's disease (CD) is an extensively investigated autoimmune condition, knowledge on early phase activation of lymphocytes, especially CD8+ Tc cells is scarce. Our aim was to investigate the calcium influx characteristics of CD8+ cells upon activation as well as the expression and function of Kv1.3 and IKCa1 lymphocyte potassium channels. METHODS: We took peripheral blood from 12 healthy controls, 23 CD children on conventional therapy and 6 severe CD children before and after infliximab therapy...
March 11, 2017: Immunology Letters
https://www.readbyqxmd.com/read/28300323/acquired-perforating-dermatosis-clinicopathological-study-of-31-cases-emphasizing-pathogenesis-and-treatment
#17
Ana Julia García-Malinis, Elena Del Valle Sánchez, María Pilar Sánchez-Salas, Elena Del Prado, Carmen Coscojuela, Yolanda Gilaberte
BACKGROUND: Acquired perforating dermatosis (APD) is a rare group of skin disorders of unknown aetiology and pathogenesis, and is associated with several systemic diseases. OBJECTIVE: We review the clinicopathological features, associated systemic diseases, and treatment response in a series of APD patients. METHODS: We conducted a retrospective observational study of all patients histologically diagnosed with APD in Hospital San Jorge (Huesca, Spain) between 2002 and 2014...
March 16, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28300301/etanercept-or-infliximab-for-psoriasis-an-independent-randomized-clinical-trial
#18
A D Burden
No abstract text is available yet for this article.
March 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28294972/potential-impact-of-diet-on-treatment-effect-from-anti-tnf-drugs-in-inflammatory-bowel-disease
#19
REVIEW
Vibeke Andersen, Axel Kornerup Hansen, Berit Lilienthal Heitmann
We wanted to investigate the current knowledge on the impact of diet on anti-TNF response in inflammatory bowel diseases (IBD), to identify dietary factors that warrant further investigations in relation to anti-TNF treatment response, and, finally, to discuss potential strategies for such investigations. PubMed was searched using specified search terms. One small prospective study on diet and anti-TNF treatment in 56 patients with CD found similar remission rates after 56 weeks among 32 patients with good compliance that received concomitant enteral nutrition and 24 with poor compliance that had no dietary restrictions (78% versus 67%, p = 0...
March 15, 2017: Nutrients
https://www.readbyqxmd.com/read/28293938/effectiveness-and-safety-of-infliximab-biosimilar-ct-p13-in-treating-ulcerative-colitis-a-real-life-experience-in-ibd-primary-centers
#20
Antonio Tursi, Leonardo Allegretta, Stefania Chiri, Nicola Della Valle, Walter Elisei, Giacomo Forti, Roberto Lorenzetti, Giammarco Mocci, Antonio Penna, Giuseppe Pranzo, Cristina Ricciardelli, Marcello Picchio
BACKGROUND: To assess the efficacy and safety of biosimilar infliximab (IFX) IFX CT-P13 in inducing and maintain remission in Ulcerative Colitis (UC) outpatients in Italian primary gastroenterology centers. METHODS: Patients were prospectively assessed at entry, after 8, 12, 24, 36, and therefore 52 weeks. Clinical activity was scored according to the Mayo score. The primary endpoint was reaching of clinical remission (Mayo score ≤2). Several secondary endpoints were clinical response to treatment, reaching of mucosal healing (MH), safety of the drug...
March 14, 2017: Minerva Gastroenterologica e Dietologica
keyword
keyword
1757
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"